Lunglife Ai Share Price (LLAI)

And then the possibility that licensing deals for outside the USA could happen at any time make this a very exciting investment

The best thing apart from being the market leader at predicting early stage lung cancer is that hospitals don’t have to pay for new equipment or training staff, they just order tests and take blood samples, no barriers to entry at all, and the hospitals and patients can benefit straight away

81.6% held by significant shareholders

Simon Raab 4,148,293 16.3

Icahn School of Medicine at Mount Sinai 2,469,842 9.7

Octopus Investments Ltd 1,968,750 7.7

Unicorn Asset Management 1,750,000 6.9

Syno Ventures Master Fund LP 1,673,668 6.6

Frederick W Gluck 1,530,596 6.0

Stifel Nicolaus & Co 1,424,784 5.7

Investec Wealth & Management 1,394,839 5.5

Livzon Pharmaceutical Group Inc 1,347,653 5.3

Lombard Odier Asset Mgt 1,268,363 4.9

Accord Data Holdings 954,048 3.7

Killik Asset Mgt 836,964 3.3

Simon Raab 4,148,293 16.3%

Icahn School of Medicine at Mount Sinai 2,469,842 9.7%

Octopus Investments Ltd 1,968,750 7.7%

Unicorn Asset Management 1,750,000 6.9%

81.6% tightly held by significant shareholders, a lot of them since IPO